Mutagenic activation reduces carcinogenic activity of ortho-aminoazotoluene for mouse liver

L P Ovchinnikova1, L A Bogdanova, V I Kaledin

  • 1Institute of Cytology and Genetics, Siberian Division of the Russian Academy of Sciences, Novosibirsk, Russia.

Insights

Pentachlorophenol inhibited the liver cancer activity of aromatic amines like 4-aminoazobenzene and ortho-aminoazotoluene in mice. This suggests the parent compound, not its metabolites, is the primary liver carcinogen.

Area of Science:

  • Toxicology
  • Hepatocarcinogenesis
  • Metabolic enzyme induction

Background:

  • Aromatic amines are known carcinogens, with their activity often modulated by metabolic processes.
  • Pentachlorophenol is recognized as an inhibitor of metabolic enzyme stimulation.

Purpose of the Study:

  • To investigate the effect of pentachlorophenol on the hepatocarcinogenic activity of 4-aminoazobenzene and ortho-aminoazotoluene.
  • To elucidate the role of metabolic activation in the carcinogenicity of ortho-aminoazotoluene.

Main Methods:

  • Administration of 4-aminoazobenzene and ortho-aminoazotoluene to suckling mice.
  • In vitro mutagenicity testing using Ames' test (S. typhimurium TA 98 strain) with liver enzyme activation.
  • Assessment of pentachlorophenol's effect on carcinogenicity and mutagenicity.

Main Results:

  • Pentachlorophenol significantly reduced the liver tumor-inducing potential of both 4-aminoazobenzene and ortho-aminoazotoluene.
  • Pentachlorophenol suppressed the mutagenic activity of these compounds in the Ames' test.
  • Enzyme induction that enhanced ortho-aminoazotoluene's mutagenicity concurrently reduced its carcinogenic effect.

Conclusions:

  • The parent compound, ortho-aminotoluene, is identified as the direct hepatocarcinogen in mice, rather than its mutagenic metabolites.
  • Pentachlorophenol acts as an inhibitor, reducing the carcinogenic and mutagenic potential of these aromatic amines.

Related Concept Videos

Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
Bioactivation and Tissue Toxicity01:25

Bioactivation and Tissue Toxicity

Bioactivation is a metabolic process that transforms less reactive substances into highly reactive metabolites, initiating tissue toxicity. This transformation can lead to various toxic effects, including carcinogenesis and teratogenesis. Reactive metabolites are classified into two main types: electrophiles and free radicals.Electrophiles are electron-deficient species and are produced primarily by the enzyme cytochrome P-450 during the metabolism of compounds containing carbon, nitrogen, or...
In-vitro Mutagenesis01:16

In-vitro Mutagenesis

To learn more about the function of a gene, researchers can observe what happens when the gene is inactivated or “knocked out,” by creating genetically engineered knockout animals. Knockout mice have been particularly useful as models for human diseases such as cancer, Parkinson’s disease, and diabetes.
Mouse Models of Cancer Study02:43

Mouse Models of Cancer Study

Mice have long served as models for studying human biology and pathology because of their phylogenetic and physiological similarity with humans. They are also easy to maintain and breed in the laboratory, and hence, many inbred strains are now available for research. Studies on mice have contributed immeasurably to our understanding of cancer biology.
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Spontaneous and Induced Mutations01:30

Spontaneous and Induced Mutations

Spontaneous mutations arise infrequently during DNA replication due to errors in the process. A key factor behind these errors is tautomeric shifts in nitrogenous bases, where bases transition from keto to enol forms or amino to imino forms. This shift can alter base-pairing rules, leading to mutations. Additionally, reactive oxygen species (ROS) arising from aerobic metabolism can damage DNA, resulting in depurination (loss of a purine base) or depyrimidination (loss of a pyrimidine base).
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...